Axtria Whitepaper: Econometric Analysis of Biopharmaceutical Transfer Pricing

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of intangible assets like intellectual property (IP) will be fundamental to future biopharmaceutical financial success. The global nature and internal structure of biopharmaceutical multinational corporations (MNCs) means that the location of commercialization is often different from where IP is developed. Therefore, understanding the financial implications of transfer pricing caused by differentials in country corporate income tax rates can legally and significantly minimize country tax liabilities.   Learn More..


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s